Tecentriq 840 mg concentrate for solution for infusion, Tiragolumab
ML43332
Phase 2 small_molecule active
Quick answer
Tecentriq 840 mg concentrate for solution for infusion, Tiragolumab for Solid tumors is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Solid tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active